8-methoxy-2,6-diaminopurine | 131287-55-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 8-methoxy-2,6-diaminopurine
• 英文别名: 8-methoxy-7H-purine-2,6-diamine
• CAS: 131287-55-3
• 化学式: C₆H₈N₆O
• 分子量: 180.169
• InChiKey: HCPQEJWMXCYZTE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  116
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  8-bromo-2,6-diaminopurine 生成 8-methoxy-2,6-diaminopurine
  参考文献：
  名称：

  XING, YI-DE;HIXSON, STEPHEN S.;ZIMMERMANN, ROBERT A., TETRAHEDRON LETT., 31,(1990) N1, C. 5849-5850

  摘要：

  DOI：

文献信息

• [EN] SUBSTITUTED PIXYL PROTECTING GROUPS FOR OLIGONUCLEOTIDE SYNTHESIS<br/>[FR] GROUPES SUBSTITUES DE PROTECTION DE PIXYLE DESTINES A UNE SYNTHESE D'OLIGONUCLEOTIDES
  申请人：ISIS PHARMACEUTICALS INC

  公开号：WO2005077966A1

  公开（公告）日：2005-08-25

  The present invention describes an improved hydroxyl protecting group of formula (1), wherein R2 and R7 are specified substituents and Q is O, S, NR10 or N(C=O)R10.

  本发明描述了一种改进的羟基保护基团，其化学式为（1），其中R2和R7是指定的取代基，Q为O、S、NR10或N(C=O)R10。
• DNA ink—near-field absorption coupling for colorimetric detection, DNA ink, chromic photoswitches, and chromic molecular ruler
  申请人：Boise State University

  公开号：US11385235B2

  公开（公告）日：2022-07-12

  The nucleotides can then be polymerized into oligomers. The design of the oligomers will depend on the design of the overall architecture. Simple architectures may be designed by any methods. However, more complex architectures may be design using software, such as caDNAno (as described at cadnano.org/docs.html, and herein incorporated by reference), to minimize errors and time. The user may input the desired shape of the architecture into the software and once finalized, the software will provide the oligomer sequences of the bricks to create the desired architecture. The length of the oligomers may be from about 10 to about 10,000, or less than about 9,000, less than about 8,000, less than about 5,000 nucleotides in length. The length of the oligomer will be optimized for the type of architecture used.

  然后，核苷酸可以聚合成低聚物。低聚物的设计取决于整体结构的设计。简单的结构可以用任何方法设计。不过，更复杂的结构可以使用软件来设计，如 caDNAno（见 cadnano.org/docs.html，在此并入作为参考），以尽量减少误差和时间。用户可将所需的结构形状输入软件，一旦最终确定，软件将提供寡聚物序列，以创建所需的结构。寡聚体的长度可从约 10 到约 10,000，或小于约 9,000、小于约 8,000、小于约 5,000 个核苷酸。寡聚体的长度将根据所使用的结构类型进行优化。
• Biological molecule based computing method based on a blocking principle
  申请人：——

  公开号：US20030073114A1

  公开（公告）日：2003-04-17

  A computational method that makes use of DNA molecules is disclosed. The method can be summarized as follows. First, a set of DNA molecules representing (by their sequences) all possible assignments to all variables of a given computational problem is generated (this is the so-called combinatorial library of the problem). Second, all the DNA molecules representing assignments which do not correspond to solutions of the problem are inactivated (blocked) for reproduction or detection. Finally, one has to check only whether any active (non-blocked) molecules remain: a solution of the problem exists if and only if any such molecules remain. In principle this allows to solve computationally difficult problems. We illustrate our method by outlining a solution for the famous satisfiability problem using both a polymerase chain reaction (PCR) method and a fluorescent quenching assay.

  本文公开了一种利用 DNA 分子的计算方法。该方法可概括如下。首先，生成一组 DNA 分子（通过其序列），代表给定计算问题所有变量的所有可能分配（这就是所谓的问题组合库）。其次，所有代表不符合问题解决方案的赋值的 DNA 分子都会被灭活（阻断），无法复制或检测。最后，我们只需检查是否仍有活跃的（未被阻断的）分子：当且仅当仍有此类分子时，才存在问题的解决方案。原则上，这可以解决计算上的难题。我们用聚合酶链式反应（PCR）方法和荧光淬灭检测法概述了著名的可满足性问题的解决方案，以此说明我们的方法。
• Inhibition of viruses
  申请人：Loakes David

  公开号：US20050043268A1

  公开（公告）日：2005-02-24

  Disclosed is a pharmaceutical composition comprising a ribonucleoside analogue in accordance with general formula (I) or (II) as herein defined in admixture with a physiologically acceptable excipient diluent or carrier.

  本发明公开了一种药物组合物，该组合物包含符合本文定义的通式（I）或（II）的核糖核苷类似物，并与生理学上可接受的赋形剂稀释剂或载体混合。
• Oligomeric compositions and methods
  申请人：Kinberger A. Garth

  公开号：US20060142232A1

  公开（公告）日：2006-06-29

  The activated oligomer compounds described herein are capable of forming bio-reversible covalent bonds with plasma proteins, in particular with human serum albumin. The plasma protein-oligomer complexes of the present invention exhibit enhanced cellular entry and significantly enhanced serum half-life.

  本文所述的活化低聚物化合物能够与血浆蛋白，特别是人血清白蛋白形成生物可逆共价键。本发明的血浆蛋白-低聚物复合物可增强进入细胞的能力，并显著延长血清半衰期。